Treating diabetes today with gliclazide MR: A matter of numbers

Diabetes, Obesity and Metabolism

Volumn 14, Issue 1 SUPPL. 1, 2012, Pages 14-19

  Avogaro, A ^a  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Cardiovascular disease; Diabetes; Gliclazide; Kidney disease; Oral antidiabetic agents

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; TOLBUTAMIDE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CARDIOVASCULAR RISK; FOLLOW UP; HEART INFARCTION; HEART PROTECTION; HUMAN; INSULIN RELEASE; LIPID PEROXIDATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; REVIEW; RISK REDUCTION; STROKE;

EID: 82255194232     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01508.x     Document Type: Review

References (53)

1. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest 2011; 121: 2094-2101.
2. Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM 2003; 96: 281-288.
3. Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP. Endothelial dysfunction in diabetes. Diabetes Care 2011; 34: S285-290.
4. Golden SH, Selvin E, Cunningham KE. Glycaemic status and cardiovascular disease in type 2 diabetes mellitus: re-visiting glycated haemoglobin targets for cardiovascular disease prevention. Diabetes Obes Metab 2007; 9: 792-798.
5. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
6. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95, 783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240.
7. Executive summary: standards of medical care in diabetes-2011. Diabetes Care 2011; 34: S4-10.
8. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008; 31: 173-175.
9. Standards of Medical Care in Diabetes-2006. Diabetes Care 2006; 29: S4-42.
10. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
11. Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
12. Chen LL, Yu F, Zeng TS, Liao YF, Li YM, Ding HC. Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes. Eur J Pharmacol 2011; 659: 296-301.
13. Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53: 298-304.
14. Yudkin JS, Richter B, Gale EAM. Intensified glucose control in type 2 diabetes-whose agenda? Lancet 2011; 377: 1220-1222.
15. Yudkin J, Richter B, Gale E. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010; 53: 2079-2085.
16. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008; 358: 2560-2572.
17. Zoungas S, Chalmers J, Patel A. 221: Intensive glucose control is renoprotective in type 2 diabetes: new analyses from ADVANCE. Diabetologia 2010; 52: S98; 46th EASD meeting 2010, Stockholm SWEDEN.
18. Gerstein H, Mann J, Yi Q et al. Albuminuria and risk of CV events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 2001; 286: 421-426.
19. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
20. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
21. Ismail-Beigi F, Craven T, Banerji MA et al. for the ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376: 419-430.
22. Zoungas S, Patel A, Chalmers J et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-1418.
23. European Agency for the Evaluation of Medicinal Products (EMEA); Committee for Medicinal Products for Human Use (CHMP). Note for guidance on clinical investigation of medicinal products in the treatment of Diabetes Mellitus 30/05/2002. CPMP/EWP/1080/00.
24. Schernthaner G, Grimaldi A, Di Mario U et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004; 34: 535-542.
25. Guillausseau PJ, Greb W. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily. Diabetes Metab 2001; 27: 133-137.
26. Jennings PE, Belch JJ. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide. Metabolism 2000; 49: 23-26.
27. Chugh SN, Dhawan R, Kishore K, Sharma A, Chugh K. Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus-a double blind randomized study. J Assoc Physicians India 2001; 49: 803-807.
28. O'Brien RC, Luo M, Balazs N. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 2000; 14: 201-206.
29. Fava D, Cassone-Faldetta M, Laurenti O, De Luca O, Ghiselli A, De Mattia G. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes. Diabet Med 2002; 19: 752-757.
30. Renier G, Mamputu JC, Serri O. Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells. Metabolism 2003; 52: 13-18.
31. Mamputu JC, Renier G. Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazide. Diabetes Obes Metab 2004; 6: 95-103.
32. Onozato ML, Tojo A, Goto A, Fujita T. Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet. Kidney Int 2004; 65: 951-960.
33. Corgnali M, Piconi L, Ihnat M, Ceriello A. Evaluation of gliclazide ability to attenuate the hyperglycaemic 'memory' induced by high glucose in isolated human endothelial cells. Diabetes Metab Res Rev 2008; 24: 301-309.
34. Sena CM, Louro T, Matafome P, Nunes E, Monteiro P, Seica R. Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. Physiol Res 2009; 58: 203-209.
35. Del Guerra S, Grupillo M, Masini M et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev 2007; 23: 234-238.
36. Kimoto K, Suzuki K, Kizaki T et al. Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 2003; 303: 112-119.
37. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446-1454.
38. Danchin N, Coste P, Ferrieres J et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for st-segment-elevation acute myocardial infarction: data from the French Registry on Acute ST-Elevation Myocardial Infarction (FAST-MI). Circulation 2008; 118: 268-276.
39. Zeller M, Danchin N, Simon D et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010; 95: 4993-5002.
40. Monami M, Balzi D, Lamanna C et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007; 23: 479-484.
41. Monami M, Luzzi C, Lamanna C et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006; 22: 477-482.
42. Scognamiglio R, Avogaro A, Vigili de Kreutzenberg S et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 2002; 51: 808-812.
43. Schramm TK, Gislason GH, Vaag A et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32: 1900-1908.
44. Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 2009; 86: 247-253.
45. Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 2004; 18: 113-119.
46. Kristiansen SB, Lofgren B, Nielsen JM et al. Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes. Diabetologia 2011; 54: 451-458.
47. Loubani M, Fowler A, Standen NB, Galinanes M. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium. Eur J Pharmacol 2005; 515: 142-149.
48. Bilinska M, Potocka J, Korzeniowska-Kubacka I, Piotrowicz R. 'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas. Coron Artery Dis 2007; 18: 455-462.
49. Jennings PE. Vascular benefits of gliclazide beyond glycemic control. Metabolism 2000; 49: 17-20.
50. Renier G, Desfaits AC, Serri O. Effect of gliclazide on monocyte-endothelium interactions in diabetes. J Diabetes Complications 2000; 14: 215-223.
51. Valmadrid CT, Klein R, Moss SE, Klein BEK. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160: 1093-1100.
52. Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 2005; 112: 179-184.
53. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009; 53: S35-S42.